- Home
- FDMT vs BGB Comparison
FDMT vs BGB Comparison
Compare FDMT & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FDMT | BGB |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 515.6M | 496.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | FDMT | BGB |
|---|---|---|
| Price | $9.74 | $11.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $31.71 | N/A |
| AVG Volume (30 Days) | ★ 800.7K | 168.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.75% |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $2.96 | $10.85 |
| 52 Week High | $12.34 | $12.65 |
Technical Indicators
Market Signals| Indicator | FDMT | BGB |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 52.87 |
| Support Level | $8.41 | $10.92 |
| Resistance Level | $9.78 | $11.51 |
| Average True Range (ATR) | 0.65 | 0.15 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 51.85 | 86.73 |
Price Performance
Historical ComparisonAbout FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
About BGB Blackstone Strategic Credit 2027 Term Fund of Beneficial Interest
Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.